BioCentury | Oct 1, 2012
Finance

3Q Stock Wrap-Up: Back in black

...progression-free survival (PFS) data Gilead Sciences Inc. (NASDAQ:GILD)/ Ipsen Group (Euronext:IPN) Gilead discontinues development of cicletanine...
BioCentury | Aug 27, 2012
Clinical News

Cicletanine: Development discontinued

...Patients received placebo, once- or twice-daily 150 mg oral cicletanine or once-daily 300 mg oral cicletanine...
...development of cicletanine in other indications. In 2008, Gilead acquired rights to develop and commercialize cicletanine...
...2005. Ipsen retains rights outside the U.S. Recordati S.p.A. (Milan:REC, Milan, Italy) markets cicletanine as Tenstaten...
BioCentury | Aug 27, 2012
Finance

Highlights of weekly biotech stock moves

...Sciences Inc. (NASDAQ:GILD) gained $0.54 to $57.29. Earlier in the week, Gilead discontinued development of cicletanine...
BioCentury | Aug 22, 2012
Clinical News

Gilead discontinues cicletanine for PAH

...Gilead Sciences Inc. (NASDAQ:GILD) discontinued development of cicletanine to treat pulmonary arterial hypertension after the diuretic...
...development of cicletanine in other indications. In 2008, Gilead acquired rights to develop and commercialize cicletanine...
...markets cicletanine as Tenstaten in France to treat hypertension under a 2005 deal with Ipsen. Cicletanine...
BioCentury | Jan 3, 2011
Strategy

Arresto's development

...regadenoson Pharmacologic stress agent for radionuclide myocardial perfusion imaging Mkt Ranexa ranolazine Chronic angina Mkt Cicletanine...
BioCentury | Aug 3, 2009
Strategy

Questions of the heart

...II testing for bronchiectasis. And Gilead has built a pulmonology pipeline to back up Letairis. Cicletanine...
BioCentury | Mar 30, 2009
Clinical News

Cicletanine: Phase II started

...Gilead began a double-blind, placebo-controlled, international Phase II trial to evaluate 150 mg of oral cicletanine...
...or twice daily or 300 mg given once daily for 12 weeks in 160 patients. Cicletanine...
...2005. Ipsen retains rights outside the U.S. Recordati S.p.A. (Milan:REC, Milan, Italy) markets cicletanine as Tenstaten...
BioCentury | Jun 2, 2008
Finance

Ebb & Flow

...added $2.34 to $55.32 last week after it acquired from assets from Navitas related to cicletanine...
...an off-patent diuretic. Gilead gained exclusive U.S. rights to regulatory data and submissions to develop cicletanine...
BioCentury | Jun 2, 2008
Company News

Gilead, Navitas Assets LLC deal

...Gilead acquired rights to develop and commercialize cicletanine in the U.S. from Navitas for an undisclosed...
...treat pulmonary arterial hypertension (PAH) by year end. Recordati S.p.A. (Milan, Italy) markets cicletanine as Tenstaten...
BioCentury | May 30, 2008
Company News

Gilead acquires cicletanine assets

...Gilead (NASDAQ:GILD) acquired from Navitas (Laramie, Wyo.) assets related to cicletanine, an off-patent diuretic. Navitas received...
...Under the deal, Gilead gained exclusive, U.S. rights to regulatory data and submissions to develop cicletanine...
...of the compound to treat PAH by year end. Recordati (Milan, Italy) markets cicletanine as Tenstaten...
Items per page:
1 - 10 of 10